While enormous efforts have been made for improving the quality and accuracy of PD-L1 assessments using tumor biopsy-based approaches [37], recent advances in liquid biopsy might not only overcome the many hurdles facing the field of identification of biomarkers in tumor biopsies, but also provide opportunities to discover novel biomarkers or to improve the accuracy of currently approved biomarkers. The gene discussed is CD274; the disease is neoplasm.